Stocks and Investing
Stocks and Investing
Wed, September 25, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Leland Gershell Maintained (CAPR) at Buy with Increased Target to $43 on, Sep 25th, 2024
Leland Gershell of Oppenheimer, Maintained "Capricor Therapeutics, Inc." (CAPR) at Buy with Increased Target from $15 to $43 on, Sep 25th, 2024.
Leland has made no other calls on CAPR in the last 4 months.
There are 2 other peers that have a rating on CAPR. Out of the 2 peers that are also analyzing CAPR, 0 agree with Leland's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Leland
- Joseph Pantginis of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $40 on, Tuesday, September 24th, 2024
- Kristen Kluska of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $8 on, Friday, September 20th, 2024
Contributing Sources